Topics

Indivior still confident in blockbuster potential of next-gen opioid addiction treatment

05:35 EST 14 Feb 2019 | Proactive Investors

Sublocade is seen as a long-term replacement for Suboxone, which is losing market share to generic competition and meant Indivior’s net revenue fell in 2018

Original Article: Indivior still confident in blockbuster potential of next-gen opioid addiction treatment

NEXT ARTICLE

More From BioPortfolio on "Indivior still confident in blockbuster potential of next-gen opioid addiction treatment"

Quick Search

Relevant Topics

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...